HE MAS is a sporadic disease characterized by a classic triad of polyostotic fibrous dysplasia, caféau-lait pigmentation of the skin, and hyper-functional endocrinopathies. The presence of 2 out of the 3 lesions is sufficient for the diagnosis. The pathogenesis of hypersecretory endocrinopathies in MAS involves postzygotic activating mutation of the cAMP-regulating protein, GNAS 1 gene product Gs␣, wherein arginine is replaced by other amino acids at position 201. 2, 3, 18 Acromegaly is an uncommon type of endocrine abnormality associated with MAS, and radiologically evident pituitary adenoma can be demonstrated in only 40-50% of affected patients. 3,4,21 Radiation therapy and medical therapy using such agents as bromocriptine or octreotide are the preferred treatment modalities, whereas surgical resection has been attempted only occasionally because of the technical difficulties involved in approaching the dysplastic skull base. To our knowledge, the literature does not contain any other description of successful transsphenoidal resection of pituitary adenoma in MAS patients with satisfactory endocrinologic outcome.
HE MAS is a sporadic disease characterized by a classic triad of polyostotic fibrous dysplasia, caféau-lait pigmentation of the skin, and hyper-functional endocrinopathies. The presence of 2 out of the 3 lesions is sufficient for the diagnosis. The pathogenesis of hypersecretory endocrinopathies in MAS involves postzygotic activating mutation of the cAMP-regulating protein, GNAS 1 gene product Gs␣, wherein arginine is replaced by other amino acids at position 201. 2, 3, 18 Acromegaly is an uncommon type of endocrine abnormality associated with MAS, and radiologically evident pituitary adenoma can be demonstrated in only 40-50% of affected patients. 3, 4, 21 Radiation therapy and medical therapy using such agents as bromocriptine or octreotide are the preferred treatment modalities, whereas surgical resection has been attempted only occasionally because of the technical difficulties involved in approaching the dysplastic skull base. To our knowledge, the literature does not contain any other description of successful transsphenoidal resection of pituitary adenoma in MAS patients with satisfactory endocrinologic outcome.
Here we report on a patient with polyostotic fibrous dysplasia, acromegaly, and a demonstrable pituitary macroadenoma who underwent neuronavigation-assisted transsphenoidal surgery.
verely compressed, and palpable thickening of the ribs was noted. The results of serological studies were as follows: basal GH, 20.4 ng/ml (reference range Ͻ 3.0 ng/ml); IGF-I, 1252.0 ng/ml (reference range 122.9-570.1 ng/ml); and PRL, 57.8 ng/ml (reference range Ͻ 25.0 ng/ml, Table 1 ). An OGTT was performed; the patient ingested 100 g of glucose, and serial blood tests were performed to determine the serum levels of glucose and GH. The results showed partial but inadequate suppression of GH levels ( Table  2) . Computed tomography showed asymmetric hyperostosis of the right frontal, zygomatic, sphenoid, and maxillary bones, with obliteration of the sphenoid sinuses ( Fig. 1A  and B ). Magnetic resonance imaging demonstrated a 17 ϫ 9-mm, nonenhancing pituitary mass and left-sided pituitary stalk deviation ( Fig. 1 C) . On the basis of physical, endocrinological, and neuroradiological examinations, MAS and an associated GH-secreting pituitary macroadenoma were diagnosed.
Operation. The patient underwent neuronavigation-guided, sublabial transsphenoidal resection of the pituitary tumor. A subfrontal approach would have been challenging given the significant amount of osseous protrusion inside the anterior cranial fossa ( Fig. 1A) .
Preoperative MR images were loaded into a Vector Vision (BrainLAB) compact system. Neuronavigation was mainly used to guide the direction of drilling through the much-thickened anterior skull base. An incision was made at the buccogingival margin and extended to ~ 8 cm in length, and the upper lip was elevated with subperiosteal dissection. The anterior nasal spine was removed, and the upper lip flap was retracted to expose the inferior portion of the pyriform aperture. The mucosa was separated from the hyperostotic maxillary bone protruding into the right nostril, and the soft, dysplastic bone was resected easily with an osteotome to recreate the right nasal cavity space. Then, the septal mucosa was elevated from the left nostril, a nasal speculum was inserted, and the septum was pushed to the right to expose the anteroinferior edge of the obliterated sphenoid sinus. At this time, the distance to the base of the sella turcica through the dysplastic skull base was measured by means of the BrainLAB software to be ~ 60 mm (Fig. 2 ). The bone was carefully drilled through under constant guidance of neuronavigation, and a tunnel was created to reach the hypophyseal fossa. Kerrison rongeurs were used to open an osseous window (0.8 ϫ 0.6 cm) at the sellar floor, and the tumor was readily identifiable as gray, soft material after the dura mater was opened. Gross-total resection was achieved under the operating microscope. The sellar floor was repaired with artificial dura and glue, and the osseous tunnel was packed with absorbable gelatin sponge and fibrous glue. The patient tolerated the procedure well. Histological examination of resected tumor tissue confirmed that the lesion was a pituitary adenoma, and the results of immunohistochemical analysis were positive for GH and PRL and negative for adrenocorticotropic hormone, thyroid-stimulating hormone, luteinizing hormone, and follicle-stimulating hormone (Fig. 3) .
Postoperative Course and Follow-Up. The patient experienced transient diabetes insipidus for 1-2 days after the operation, but the condition resolved without treatment. His visual acuity remained unchanged and there was no evidence of cerebrospinal fluid leak. Endocrinological testing revealed reduction of basal serum GH, IGF-I and PRL levels to the reference range ( Table 1 ). Postoperative OGTTs were performed at 2 weeks and 8 months after the operation, and the results were within normal limits ( Table 2 ). Brain MR imaging at 2 weeks and 8 months after the operation demonstrated complete resection of the sellar mass without evidence of stalk deviation (Fig. 4 ). The patient is currently being followed up by the endocrinological service for management of MAS.
Discussion
This report describes a patient with MAS, acromegaly, and a GH-secreting pituitary adenoma who underwent neuronavigation-guided transsphenoidal surgery. More than 60 years ago, McCune 18 and Albright and colleagues 2 identified a syndrome comprising a classic triad of precocious puberty, polyostotic fibrous dysplasia, and café-au-lait cutaneous macules. Although sexual precocity, occurring especially often in female patients, is the most frequently recognized endocrine disturbance associated with MAS, it is now understood that other hypersecretory endocrinopathies may also accompany this disorder, including hyperthyroidism, 5, 11, 15, 17, 18 hyperprolactinemia, 4, 6, 7, 13 and hypophosphatemic osteomalacia. 15, 17 Recent advances revealed that MAS results from sporadic somatic activating mutations of the ␣ subunit of the G protein (Gs␣) that stimulates cAMP formation in early development, thus creating a mosaic population of cells that affect multiple organ systems. 24, 25 Acromegaly is a rare form of endocrinopathy associated with MAS, and less than half of affected patients show radiological evidence of a pituitary adenoma. 12, 16, 21 Sakaki et al. 23 reviewed 8 cases of MAS with acromegaly and immunohistochemical evidence of GH-secreting adenoma and found that more than half of the tumors also secreted PRL, which suggests frequent occurrence of bimorphous or plurimorphous tumors in MAS patients. This observation is consistent with our findings in the present case. The management of MAS involves treating fibrous dysplasia and the associated endocrine abnormalities. The goal of treating patients with GH-secreting adenomas is to lower serum GH and IGF-I levels to their respective reference ranges because of the serious comorbidities caused by excessive GH. Moreover, although the natural history of MAS or polyostotic fibrous dysplasia is poorly understood, the potential synergistic effect of elevated serum GH levels on dysplastic bone formation is particularly worrisome. Thus, we believe that when a GH-secreting adenoma occurs in a patient with MAS, treatment should be initially fo-cused on the adenoma and the fibrous dysplasia should be addressed subsequently. We consider endocrinological control to be satisfactory if the serum GH concentration can be reduced to Ͻ 1 ng/mL after a loading dose of glucose.
Although surgery is usually the treatment of choice for acromegaly, other treatment modalities, including radiation therapy 4, 19 and administration of a long-acting somatostatin analog, 9, 10, 21 have been reported in the literature. Nevertheless, pharmacological therapy such as octreotide administration has primarily been studied as a secondary treatment, 8, 20 and fractionated radiation therapy may lead to sarcomatous transformation of dysplastic bones and should probably be avoided. 19, 22 Stereotactic radiosurgery allows focal delivery of high doses of radiation and is superior to conventional radiotherapy for recurrent acromegaly after unsuccessful surgery, 14 but its efficacy and application as the primary treatment for GH-secreting adenoma have not yet been established.
Transsphenoidal surgery for acromegaly in MAS patients is complicated by 2 anatomical factors. Fibrous dysplasia in most MAS patients involves the skull base; 7, 17 thus, it is difficult and potentially dangerous to approach the much-thickened sphenoid and ethmoid bones without intraoperative directional guidance. Moreover, many investigators have reported increased vasculature in the osseous structures surrounding the pituitary, further hindering its access. 1, 21, 23 A thorough search of the English literature revealed reports of 10 cases in which patients with MAS and acromegaly had undergone surgical resection, in addition to the present case (Table 3 ). In 8 out of the 11 reported cases, a more invasive transfrontal or subfrontal approach was used with variable success and usually significant morbidity. Transsphenoidal surgery was attempted in 3 previ-ous cases 4, 6, 11 (twice in 1 of those 3), but no details of the procedures were reported and none achieved satisfactory endocrinological control of the disease.
Conclusions
We have reported on a patient with MAS and acromegaly who underwent neuronavigation-guided transsphenoidal surgery. There were no complications during the operation and the short-term outcome was excellent, with radiologically complete resection of the tumor and significant reduction of endocrinological markers to the normal levels. The serum alkaline phosphatase level, which reflects fibrous dysplasia, was slightly reduced as well. Neuronavigation provided important intraoperative anatomical guidance such that the opening of the bone window and the resection of the tumor could be achieved in more prudent fashion. These factors contributed to the good outcome of our case. FIG. 4. Postoperative neuroimages. A: Sagittal reconstruction of a head CT demonstrates the tunnel through the dysplastic anterior skull base that was made to reach the sella turcica. B: Axial MR image obtained 2 weeks after surgery shows the mixed signal consistent with packing material, which is usually absorbed within 3-6 months after an operation C: Axial MR image obtained 8 months after the operation shows that mixed signal consistent with packing material is no longer present-indicating that the material was absorbed-and there is no evidence of tumor.
Our experience suggests that neuronavigation-guided transsphenoidal resection of pituitary adenoma may provide good outcomes for patients with MAS.
